|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: UBE2U |
Gene summary for UBE2U |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | UBE2U | Gene ID | 148581 |
| Gene name | ubiquitin conjugating enzyme E2 U | |
| Gene Alias | UBE2U | |
| Cytomap | 1p31.3 | |
| Gene Type | protein-coding | GO ID | GO:0000209 | UniProtAcc | A0A140VJY9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 148581 | UBE2U | HTA11_7663_2000001011 | Human | Colorectum | SER | 7.76e-08 | 3.34e-01 | 0.0131 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00104981 | Colorectum | SER | proteasomal protein catabolic process | 132/2897 | 490/18723 | 3.08e-11 | 5.55e-09 | 132 |
| GO:00431611 | Colorectum | SER | proteasome-mediated ubiquitin-dependent protein catabolic process | 105/2897 | 412/18723 | 7.48e-08 | 4.70e-06 | 105 |
| GO:00002091 | Colorectum | SER | protein polyubiquitination | 58/2897 | 236/18723 | 1.69e-04 | 3.18e-03 | 58 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| UBE2U | SNV | Missense_Mutation | novel | c.332C>T | p.Ala111Val | p.A111V | Q5VVX9 | protein_coding | deleterious(0.03) | benign(0.255) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
| UBE2U | SNV | Missense_Mutation | novel | c.415C>A | p.Leu139Met | p.L139M | Q5VVX9 | protein_coding | tolerated(0.47) | benign(0.024) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
| UBE2U | SNV | Missense_Mutation | novel | c.587N>T | p.Arg196Ile | p.R196I | Q5VVX9 | protein_coding | deleterious(0) | possibly_damaging(0.571) | TCGA-QS-A5YQ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| UBE2U | SNV | Missense_Mutation | novel | c.202N>G | p.Pro68Ala | p.P68A | Q5VVX9 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-ZP-A9CY-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| UBE2U | SNV | Missense_Mutation | c.103N>A | p.Glu35Lys | p.E35K | Q5VVX9 | protein_coding | tolerated(0.47) | benign(0.054) | TCGA-55-8302-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| UBE2U | SNV | Missense_Mutation | c.11N>A | p.Arg4Lys | p.R4K | Q5VVX9 | protein_coding | tolerated(0.09) | benign(0.023) | TCGA-22-4601-01 | Lung | lung squamous cell carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
| UBE2U | SNV | Missense_Mutation | rs370723679 | c.256G>T | p.Gly86Cys | p.G86C | Q5VVX9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-33-AASB-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| UBE2U | SNV | Missense_Mutation | novel | c.645G>T | p.Met215Ile | p.M215I | Q5VVX9 | protein_coding | tolerated(0.22) | benign(0.006) | TCGA-56-8628-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| UBE2U | SNV | Missense_Mutation | novel | c.530N>T | p.Ser177Ile | p.S177I | Q5VVX9 | protein_coding | tolerated(0.08) | benign(0.041) | TCGA-63-7020-01 | Lung | lung squamous cell carcinoma | Male | Unknown | I/II | Unknown | Unknown | SD |
| UBE2U | SNV | Missense_Mutation | novel | c.124N>A | p.Gly42Ser | p.G42S | Q5VVX9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-90-A4ED-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |